Key Takeaway: Werewolf Therapeutics, Inc. reported its financial results for the first quarter of 2025 and provided a business update. The report includes key financial metrics and insights into the company's ongoing projects and future plans. Further details about the company's performance and strategic direction were also discussed.
Price reaction · baseline $0.921 (2025-05-07 close) · hit pre-market · 1 other HOWL headline(s) in the window, move may be shared
day 0 close
-5.5%
day 1 · peak
-13.2%
day 3
+10.7%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+25%
120-day peak, hindsight
Typical move
15%
average across 6 past catalysts
Lead asset
WTX-330
Phase 1 · Advanced or Metastatic Solid Tumors
Full Press Release Details
May 8, 2025
Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
WATERTOWN, Mass., May 8, 2025 — Werewolf Therapeutics, Inc. (the “Company” or “Werewolf”)...